<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761939</url>
  </required_header>
  <id_info>
    <org_study_id>EluNIR-005</org_study_id>
    <nct_id>NCT04761939</nct_id>
  </id_info>
  <brief_title>BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial</brief_title>
  <official_title>BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medinol Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medinol Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Device:&#xD;
&#xD;
      EluNIR Ridaforolimus Eluting Coronary Stent System - (hereafter referred to as EluNIR) 2.25&#xD;
      mm diameter (8 mm, 12 mm, 15 mm, 17 mm, 20 mm, 24 mm, 28 mm and 33 mm length)&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To further assess the safety and efficacy of the small diameter (2.25 mm) Ridaforolimus&#xD;
      Eluting Stent - EluNIR.&#xD;
&#xD;
      Subject Population:&#xD;
&#xD;
      Subjects who underwent PCI for angina (stable or unstable), silent ischemia (in absence of&#xD;
      symptoms a visually estimated target lesion diameter stenosis of ≥70%, a positive&#xD;
      non-invasive stress test, or FFR ≤0.80 must be present), NSTEMI, and recent STEMI (&gt;24 hours&#xD;
      from initial presentation and stable) with attempted implantation of a 2.25 mm diameter&#xD;
      EluNIR stent.&#xD;
&#xD;
      Trial Design and Methods:&#xD;
&#xD;
      This is a prospective, multi-center, single-arm, open-label clinical trial. Clinical&#xD;
      follow-up for all patients will be performed at 30 days 6 months, and 1 year after the&#xD;
      procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 31, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>At 30 days</time_frame>
    <description>Combined early efficacy and safety endpoint:&#xD;
MACE at 30 days for all patients enrolled. MACE is defined as the composite of cardiac death, any MI, or ischemia-driven TLR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TLF</measure>
    <time_frame>At 6 month</time_frame>
    <description>Combined late efficacy and safety endpoint:&#xD;
Target Lesion Failure (TLF) at 6 months (evaluated for the first 50% of patients enrolled) Defined as the composite of cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TLF</measure>
    <time_frame>6 Months and 1 Year</time_frame>
    <description>Target Lesion Failure at 6 months (for all patients enrolled) and 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>30 Days, 6 Months &amp; 1 Year</time_frame>
    <description>Device success is defined as achievement of a final in-stent residual diameter stenosis of &lt;30% (by QCA), using the EluNIR 2.25 mm stent only and without a device malfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion success</measure>
    <time_frame>30 Days, 6 Months &amp; 1Year</time_frame>
    <description>Lesion success is defined as achievement of a final in-stent residual diameter stenosis of &lt;30% (by QCA) using any percutaneous method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>30 Days, 6 Months &amp; 1Year</time_frame>
    <description>Procedure success is defined as achievement of a final in-stent diameter stenosis of &lt;30% (by QCA) using the assigned device and/or with any adjunctive devices, without the occurrence of cardiac death, Q wave or non-Q wave MI, or repeat revascularization of the target lesion during the hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>30 Days, 6 Months &amp; 1 Year</time_frame>
    <description>TVF; the composite rate of death, target vessel related MI or ischemia-driven TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>30 Days, 6 Months &amp; 1Year</time_frame>
    <description>MACE; the composite rate of cardiac death, any MI or ischemia-driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 Days, 6 Months &amp; 1 Year</time_frame>
    <description>cardiac death, vascular death, non cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>30 Days, 6 Months &amp; 1Year</time_frame>
    <description>Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MI</measure>
    <time_frame>30 Days, 6 Months &amp; 1Year</time_frame>
    <description>Post-PCI (Type 4a) and post-CABG (Periprocedural) MIs (Type 5), Periprocedural MIs will be defined based on the SCAI definitions and Spontaneous MI (MI Type I) will be defined based on the Universal Definition of Myocardial Infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel related MI</measure>
    <time_frame>30 Days, 6 Months &amp; 1 Year</time_frame>
    <description>Target vessel related MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven TLR</measure>
    <time_frame>30 Days, 6 Months &amp; 1 Year</time_frame>
    <description>TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia-driven TVR</measure>
    <time_frame>30 Days, 6 Months &amp; 1Year</time_frame>
    <description>TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>30 Days, 6Months &amp; 1Year</time_frame>
    <description>ARC definite and probable (Circulation 2007;115:2344-51)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Coronary Stenosis</condition>
  <condition>Coronary Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Cardiovascular Diseases</condition>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>EluNIR Ridaforolimus Eluting Coronary Stent System</intervention_name>
    <description>The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:&#xD;
Stent - a pre-mounted Cobalt Chromium (CoCr) alloy based stent - 2.25 mm Diameter and 8mm, 12mm, 15mm, 17mm, 20mm, 24mm, 28mm and 33mm length&#xD;
Delivery System - Rapid Exchange (RX) Coronary System&#xD;
Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®&#xD;
Ridaforolimus drug - CAS Registry Number: 572924-54-0</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who underwent PCI for angina (stable or unstable), silent ischemia (in absence of&#xD;
        symptoms a visually estimated target lesion diameter stenosis of ≥70%, a positive&#xD;
        non-invasive stress test, or FFR ≤0.80 must be present), NSTEMI, and recent STEMI (&gt;24&#xD;
        hours from initial presentation and stable) with attempted implantation of a 2.25 mm&#xD;
        diameter EluNIR stent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age ≥ 18 years. 2. Patient with an indication for PCI including angina (stable or&#xD;
        unstable), silent ischemia (in absence of symptoms a visually estimated target lesion&#xD;
        diameter stenosis of ≥70%, a positive non-invasive stress test, or FFR ≤0.80 must be&#xD;
        present), NSTEMI, or recent STEMI. For STEMI the time of presentation to the first treating&#xD;
        hospital, whether a transfer facility or the study hospital, must be &gt;24 hours prior to&#xD;
        enrollment and enzyme levels (CK-MB or Troponin) demonstrating that either or both enzyme&#xD;
        levels have peaked.&#xD;
&#xD;
        3. An attempt (whether successful or not) was made to implant a 2.25 mm EluNIR stent (Stent&#xD;
        was advanced beyond the guiding catheter).&#xD;
&#xD;
        4. Non-target lesion PCIs are allowed depending on the time interval and conditions as&#xD;
        follows:&#xD;
&#xD;
          1. During Index Procedure:&#xD;
&#xD;
             if successful and uncomplicated defined as: &lt;50% visually estimated residual diameter&#xD;
             stenosis, TIMI Grade 3 flow, no dissection ≥ NHLBI type C, no perforation, no&#xD;
             persistent ST segment changes, no prolonged chest pain, no TIMI major or BARC type 3&#xD;
             bleeding.&#xD;
&#xD;
          2. Less than 24 hours prior to Index Procedure:&#xD;
&#xD;
        Not allowed (see exclusion criteria #2). c. 24 hours-30 days prior to Index Procedure: i.&#xD;
        PCI of non-target vessels 24 hours to 30 days prior to the index procedure if successful&#xD;
        and uncomplicated as defined above.&#xD;
&#xD;
        ii. In addition, in cases where non-target vessel PCI has occurred 24-72 hours prior to the&#xD;
        index procedure, at least 2 sets of cardiac biomarkers must have been drawn at least 6 and&#xD;
        12 hours after the non-target vessel PCI.&#xD;
&#xD;
        iii. If cardiac biomarkers are initially elevated above the local laboratory upper limit of&#xD;
        normal, serial measurements must demonstrate that the biomarkers are falling.&#xD;
&#xD;
        d. Over 30 days prior to Index Procedure: PCI of non-target lesions performed greater than&#xD;
        30 days prior to index procedure whether or not successful and uncomplicated.&#xD;
&#xD;
        5. Patient or legal guardian is willing and able to provide informed written consent and&#xD;
        comply with follow-up visits and testing schedule.&#xD;
&#xD;
        Angiographic inclusion criteria (visual estimate):&#xD;
&#xD;
        6. Target lesion(s) must be located in a native coronary artery or bypass graft conduit&#xD;
        with visually estimated diameter of ≥2.25 mm to ≤2.5 mm.&#xD;
&#xD;
        7. Complex lesions are allowed including calcified lesions (lesion preparation with&#xD;
        scoring/cutting and rotational atherectomy are allowed), presence of thrombus, CTO,&#xD;
        bifurcation lesions, ostial RCA lesions, tortuous lesions, bare metal stent restenotic&#xD;
        lesions, protected left main lesions, and saphenous vein graft lesions.&#xD;
&#xD;
        8. Overlapping stents are allowed as long as at least one of the stents implanted is the&#xD;
        EluNIR 2.25 mm diameter stent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. STEMI within 24 hours of initial time of presentation to the first treating hospital,&#xD;
             whether at a transfer facility or the study hospital or in whom enzyme levels (either&#xD;
             CK-MB or Troponin) have not peaked.&#xD;
&#xD;
          2. PCI within the 24 hours preceding the index procedure.&#xD;
&#xD;
          3. Non-target lesion PCI in the target vessel 24 hours to 30 days.&#xD;
&#xD;
          4. Planned staged procedures.&#xD;
&#xD;
          5. Brachytherapy in conjunction with the index procedure.&#xD;
&#xD;
          6. History of stent thrombosis.&#xD;
&#xD;
          7. Cardiogenic shock (defined as persistent hypotension (systolic blood pressure &lt;90&#xD;
             mm/Hg for more than 30 minutes) or requiring pressors or hemodynamic support,&#xD;
             including IABP.&#xD;
&#xD;
          8. Subject is intubated.&#xD;
&#xD;
          9. Known LVEF &lt;30%.&#xD;
&#xD;
         10. Relative or absolute contraindication to DAPT for 6 months in non-ACS patients and 12&#xD;
             months in ACS patients (including planned surgeries that cannot be delayed, or subject&#xD;
             is indicated for chronic oral anticoagulant treatment).&#xD;
&#xD;
         11. eGFR &lt;30 mL/min&#xD;
&#xD;
         12. Hemoglobin &lt;10 g/dL.&#xD;
&#xD;
         13. Platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3.&#xD;
&#xD;
         14. White blood cell (WBC) count &lt;3,000 cells/mm3.&#xD;
&#xD;
         15. Clinically significant liver disease.&#xD;
&#xD;
         16. Active peptic ulcer or active bleeding from any site.&#xD;
&#xD;
         17. Bleeding from any site within the prior 8 weeks requiring active medical or surgical&#xD;
             attention.&#xD;
&#xD;
         18. If femoral access is planned, significant peripheral arterial disease which precludes&#xD;
             safe insertion of a 6F sheath.&#xD;
&#xD;
         19. History of bleeding diathesis or coagulopathy or will refuse blood transfusions.&#xD;
&#xD;
         20. Cerebrovascular accident or transient ischemic attack within the past 6 months, or any&#xD;
             permanent neurologic defect attributed to CVA.&#xD;
&#xD;
         21. Known allergy to the study stent components cobalt, nickel, chromium, molybdenum,&#xD;
             Carbosil®, PBMA, or limus drugs (ridaforolimus, zotarolimus, tacrolimus, sirolimus,&#xD;
             everolimus, or similar drugs or any other analogue or derivative or similar&#xD;
             compounds).&#xD;
&#xD;
         22. Known allergy to protocol-required concomitant medications such as aspirin, or DAPT&#xD;
             (clopidogrel, prasugrel, ticagrelor), or heparin and bivalirudin, or iodinated&#xD;
             contrast that cannot be adequately pre-medicated.&#xD;
&#xD;
         23. Any co-morbid condition that may cause non-compliance with the protocol (e.g.&#xD;
             dementia, substance abuse, etc.) or reduced life expectancy to &lt;24 months (e.g.&#xD;
             cancer, severe heart failure, severe lung disease).&#xD;
&#xD;
         24. Patient is participating in or plans to participate in any other investigational drug&#xD;
             or device clinical trial that has not reached its primary endpoint.&#xD;
&#xD;
         25. Women who are pregnant or breastfeeding.&#xD;
&#xD;
         26. Women who intend to become pregnant within 12 months after the index procedure (women&#xD;
             of child-bearing potential who are sexually active must agree to use a reliable method&#xD;
             of contraception from the time of screening through 12 months after the index&#xD;
             procedure).&#xD;
&#xD;
         27. Patient has received an organ transplant or is on a waiting list for an organ&#xD;
             transplant.&#xD;
&#xD;
         28. Patient is receiving or scheduled to receive chemotherapy within 30 days before or any&#xD;
             time after the index procedure.&#xD;
&#xD;
         29. Patient is receiving oral or intravenous immunosuppressive therapy or has known&#xD;
             life-limiting immunosuppressive or autoimmune disease (e.g., HIV). Corticosteroids are&#xD;
             allowed.&#xD;
&#xD;
             Angiographic Exclusion Criteria (visual estimate):&#xD;
&#xD;
         30. Unprotected left main lesions ≥30%, or planned left main intervention.&#xD;
&#xD;
         31. Bifurcation lesions with planned dual stent implantation.&#xD;
&#xD;
         32. Stenting of lesions due to DES restenosis.&#xD;
&#xD;
         33. Occlusive thrombus and/or a thrombus requiring thrombectomy in a target vessel&#xD;
&#xD;
         34. Another lesion in a target or non-target vessel (including all side branches) is&#xD;
             present that requires or has a high probability of requiring PCI within 12 months&#xD;
             after the index procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoram Richter, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillel Yafe Medical Center</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>April 4, 2021</last_update_submitted>
  <last_update_submitted_qc>April 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

